SafetySafety & DosingZAVZPRETTM (zavegepant) was generally well tolerated in two pivotal clinical trials1,2
Most AEs were mild or moderate1,2
Not associated with sedation or fatigue in clinical trials1,2
Contraindications: Hypersensitivity to ZAVZPRET or any of its components.
Warnings and Precautions: Hypersensitivity reactions, including facial swelling and urticaria, have occurred with ZAVZPRET. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy.Not contraindicated in patients with stable cardiovascular disease or risk factors.1,2*Taste disorders include dysgeusia and ageusiaPrescribing informationLoadingPrescribing informationLoadingSafety & Dosing
Request a representativeConnect with a sales representative to learn moreReferences:Zavzpret. Package insert. Pfizer Inc.Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(13):209-217. doi:10.1016/S1474-4422(22)00517-8
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
You are now leaving Pfizer
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-MCL-USA-0367
INDICATION
ZAVZPRETTM (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.
Important Safety Information Contraindications: Hypersensitivity to ZAVZPRET or any of its components.
Warnings and Precautions: Hypersensitivity reactions, including facial swelling and urticaria, have occurred with ZAVZPRET. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy.
Adverse Reactions: Most common adverse reactions (occurring in ≥2% of patients treated with ZAVZPRET and greater than placebo) for ZAVZPRET vs placebo were taste disorders including dysgeusia and ageusia (18% vs 4%), nausea (4% vs 1%), nasal discomfort (3% vs 1%), and vomiting (2% vs 1%).
Drug Interactions: Avoid use with drugs that inhibit or induce OATP1B3 or NTCP transporters. Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration.
Use in Specific Populations: Hepatic Impairment: Avoid use in patients with severe hepatic impairment. Renal impairment: Avoid use of ZAVZPRET in patients with creatinine clearance (CLcr) less than 30 mL/min.
Please click here for fullPrescribing Information.IndicationZAVZPRET™️ (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.